Linac-Pet Scan Opco Limited

The medical center is at the forefront of developing personalized treatment strategies for prostate cancer, utilizing cutting-edge technologies such as artificial intelligence and advanced imaging techniques. The focus is on optimizing radiotherapy and androgen deprivation therapy to enhance patient outcomes.

• AI-driven Radiotherapy Personalization
• PSMA PET/CT Imaging
• Ultra-hypofractionated Radiotherapy

By integrating AI with imaging, the center aims to reduce treatment duration and improve patient convenience without compromising disease-free survival.

Specializing in the treatment of solid tumors, the center is pioneering the use of novel drug combinations to enhance therapeutic efficacy. The focus is on evaluating the safety and pharmacokinetics of innovative treatments to improve patient care.

• Intravenous Fixed-Dose Combinations
• Tiragolumab and atezolizumab
• Safety and Tolerability Studies

Through rigorous clinical trials, the center is committed to advancing the understanding of combination therapies in oncology.

The center is leading research in the treatment of oligo-metastatic hormone-sensitive prostate cancer, focusing on innovative radioligand therapies. The goal is to assess the impact of Lutetium-177-PSMA on disease progression and patient survival.

• 177Lu-PSMA Radioligand Therapy
• Progression-Free Survival Studies
• Comparative Treatment Analysis

By comparing new therapies with standard care, the center aims to establish more effective treatment protocols for prostate cancer patients.